Erratum: Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro (Cell Reports (2017) 21(2) (508–516) (S2211124717313311) (10.1016/j.celrep.2017.09.043));Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro

Cell Reports

Volumn 21, Issue 2, 2017, Pages 508-516

  Hassell, Bryan A ^a,b   Goyal, Girija ^a   Lee, Esak ^a,c   Sontheimer Phelps, Alexandra ^a,d   Levy, Oren ^a   Chen, Christopher S ^a,c   Ingber, Donald E ^a,b,e  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Boston University   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

chemotherapy; EGFR inhibitor; invasion; lung cancer; mechanical; mechanobiology; microfluidic; organ on chip; persister cell; tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE; ROCILETINIB; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ARTICLE; BIOLOGICAL MODEL; BREATHING; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DORMANCY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMAL RESIDUAL DISEASE; NON SMALL CELL LUNG CANCER; ORGAN CHIP MODEL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR INVASION; TUMOR MICROENVIRONMENT; CELL CULTURE; CYTOLOGY; DRUG EFFECT; LAB ON A CHIP; LUNG TUMOR; METABOLISM; PATHOLOGY; RESPIRATORY MUCOSA;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; HUMANS; LAB-ON-A-CHIP DEVICES; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION;

EID: 85030836956     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.06.028     Document Type: Erratum

References (37)

1. Benam, B.K.H., Novak, R., Nawroth, J., Hirano-kobayashi, M., Ferrante, T.C., Choe, Y., Prantil-baun, R., James, C., Bahinski, A., Parker, K.K., Ingber, D.E., Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 5 (2016), 456–466.e4.
2. Benam, K.H., Villenave, R., Lucchesi, C., Varone, A., Hubeau, C., Lee, H.-H., Alves, S.E., Salmon, M., Ferrante, T.C., Weaver, J.C., et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat. Methods 13 (2016), 151–157.
3. Bhatia, S.N., Ingber, D.E., Microfluidic organs-on-chips. Nat. Biotechnol. 32 (2014), 760–772.
4. Chabon, J.J., Simmons, A.D., Lovejoy, A.F., Esfahani, M.S., Newman, A.M., Haringsma, H.J., Kurtz, D.M., Stehr, H., Scherer, F., Karlovich, C.A., et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun., 7, 2016, 11815.
5. Choi, Y., Hyun, E., Seo, J., Blundell, C., Kim, H.C., Lee, E., Lee, S.H., Moon, A., Moon, W.K., Huh, D., A microengineered pathophysiological model of early-stage breast cancer. Lab Chip 15 (2015), 3350–3357.
6. Elfer, K.N., Sholl, A.B., Wang, M., Tulman, D.B., Mandava, S.H., Lee, B.R., Brown, J.Q., ‘DRAQ5 and eosin (‘D&E’) as an analog to hematoxylin and eosin for rapid fluorescence histology of fresh tissues. PLoS One, 11, 2016, e0165530.
7. Enewold, L., Mechanic, L.E., Bowman, E.D., Zheng, Y.-L.L., Yu, Z., Trivers, G., Alberg, A.J., Harris, C.C., Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 18 (2009), 215–222.
8. Fidler, I.J., Wilmanns, C., Staroselsky, A., Radinsky, R., Dong, Z., Fan, D., Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 13 (1994), 209–222.
9. Finocchiaro, G., Toschi, L., Gianoncelli, L., Baretti, M., Santoro, A., Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann. Transl. Med., 3, 2015, 83.
10. Gazdar, A.F., Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28:Suppl 1 (2009), S24–S31.
11. Gould, S.E., Junttila, M.R., de Sauvage, F.J., Translational value of mouse models in oncology drug development. Nat. Med. 21 (2015), 431–439.
12. Hackam, D.G., Redelmeier, D.A., Translation of research evidence from animals to humans. JAMA 296 (2006), 1731–1732.
13. Holmgren, L., O'Reilly, M.S., Folkman, J., Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1 (1995), 149–153.
14. Huang, L., Fu, L., Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm. Sin. B 5 (2015), 390–401.
15. Huh, D., Matthews, B.D., Mammoto, A., Montoya-Zavala, M., Hsin, H.Y., Ingber, D.E., Reconstituting organ-level lung functions on a chip. Science 328 (2010), 1662–1668.
16. Huh, D., Leslie, D.C., Matthews, B.D., Fraser, J.P., Jurek, S., Hamilton, G.A., Thorneloe, K.S., McAlexander, M.A., Ingber, D.E., A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci. Transl. Med., 4, 2012, 159ra147.
17. Jain, A., Barrile, R., van der Meer, A.D., Mammoto, A., Mammoto, T., De Ceunynck, K., Aisiku, O., Otieno, M.A., Louden, C.S., Hamilton, G.A., et al. A primary human lung alveolus-on-a-chip model of intravascular thrombosis for assessment of therapeutics. Clin. Pharmacol. Ther., 2017, 10.1002/cpt.742 Published online May 17, 2017.
18. Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
19. Killion, J.J., Radinsky, R., Fidler, I.J., Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 17 (1999), 279–284.
20. Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957.
21. Morgillo, F., Della Corte, C.M., Fasano, M., Ciardiello, F., Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open, 1, 2016, e000060.
22. Pao, W., Chmielecki, J., Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer. 10 (2010), 760–774.
23. Portillo-Lara, R., Annabi, N., Microengineered cancer-on-a-chip platforms to study the metastatic microenvironment. Lab Chip 16 (2016), 4063–4081.
24. Ramirez, M., Rajaram, S., Steininger, R.J., Osipchuk, D., Roth, M.A., Morinishi, L.S., Evans, L., Ji, W., Hsu, C., Thurley, K., et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun., 7, 2016, 10690.
25. Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., et al., Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
26. Sadiq, A.A., Salgia, R., MET as a possible target for non-small-cell lung cancer. J. Clin. Oncol. 31 (2013), 1089–1096.
27. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 2011, 75ra26.
28. Sequist, L.V., Soria, J.-C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., Papadimitrakopoulou, V., Solomon, B.J., Oxnard, G.R., Dziadziuszko, R., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709.
29. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J. Clin. 67 (2017), 7–30.
30. Skardal, A., Devarasetty, M., Rodman, C., Atala, A., Soker, S., Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. Ann. Biomed. Eng. 43 (2015), 2361–2373.
31. Sordella, R., Bell, D.W., Haber, D.A., Settleman, J., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004), 1163–1167.
32. Stewart, E.L., Tan, S.Z., Liu, G., Tsao, M.S., Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl. Lung Cancer Res. 4 (2015), 67–81.
33. Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
34. Umekawa, K., Kimura, T., Kudoh, S., Suzumura, T., Oka, T., Nagata, M., Mitsuoka, S., Matsuura, K., Nakai, T., Yoshimura, N., et al. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res. Notes, 6, 2013, 139.
35. Yousem, S.A., Beasley, M.B., Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch. Pathol. Lab. Med. 131 (2007), 1027–1032.
36. Zhai, W., Lim, T.K., Zhang, T., Phang, S., Tiang, Z., Guan, P., Ng, M., Lim, J.Q., Yao, F., Li, Z., et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun., 8, 2017, 4565.
37. Zhao, B.X., Wang, J., Song, B., Wei, H., Lv, W.P., Tian, L.M., Li, M., Lv, S., Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation. Mol. Med. Rep. 11 (2015), 2767–2774.